Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Hypera S.A. (HYPMY)

Compare
3.4000
+0.1000
+(3.03%)
At close: April 1 at 4:00:00 PM EDT
Loading Chart for HYPMY
  • Previous Close 3.3000
  • Open 3.3000
  • Bid 3.3200 x 40000
  • Ask 3.4700 x 40000
  • Day's Range 3.3000 - 3.3000
  • 52 Week Range 2.6400 - 6.5600
  • Volume 264
  • Avg. Volume 7,423
  • Market Cap (intraday) 2.147B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 9.19
  • EPS (TTM) 0.3700
  • Earnings Date Apr 23, 2025
  • Forward Dividend & Yield 0.21 (6.12%)
  • Ex-Dividend Date Apr 4, 2025
  • 1y Target Est --

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

www.hypera.com.br

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HYPMY

View More

Performance Overview: HYPMY

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .

YTD Return

HYPMY
13.33%
IBOVESPA (^BVSP)
9.03%

1-Year Return

HYPMY
48.14%
IBOVESPA (^BVSP)
3.27%

3-Year Return

HYPMY
53.69%
IBOVESPA (^BVSP)
7.88%

5-Year Return

HYPMY
20.49%
IBOVESPA (^BVSP)
84.80%

Compare To: HYPMY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HYPMY

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    2.12B

  • Enterprise Value

    3.45B

  • Trailing P/E

    9.21

  • Forward P/E

    11.14

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.66

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    2.67

  • Enterprise Value/EBITDA

    8.91

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.88%

  • Return on Assets (ttm)

    4.57%

  • Return on Equity (ttm)

    11.29%

  • Revenue (ttm)

    7.44B

  • Net Income Avi to Common (ttm)

    1.33B

  • Diluted EPS (ttm)

    0.3700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.74B

  • Total Debt/Equity (mrq)

    77.65%

  • Levered Free Cash Flow (ttm)

    1.31B

Research Analysis: HYPMY

View More

Company Insights: HYPMY

Research Reports: HYPMY

View More

People Also Watch